The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation

Arthritis and Rheumatism

Volumn 39, Issue 3, 1996, Pages 515-521

  Nickerson Nutter, Cheryl L ^a,b   Medvedeff, Eugene D ^a  

^a BAYER CORPORATION   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; BAY Y 1015; COLLAGEN TYPE 2; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; N [2 CYCLOHEPTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETYL]METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL INFILTRATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; EXUDATE; FEMALE; INFLAMMATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; EXUDATES AND TRANSUDATES; FEMALE; HYDROXYUREA; INFLAMMATION; LEUKOTRIENE B4; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; QUINOLINES; TIME FACTORS; ZYMOSAN;

EID: 0029866858     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390320     Document Type: Article

References (34)

1. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH: Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264-265, 1980
2. 5 is formed in human neutrophils after dietary supplementation with icosapentaenoic acid. Proc Natl Acad Sci U S A 82:1540-1543, 1985
3. Wedmore CV, Williams TJ: Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289: 646-650, 1981
4. Levine JD, Lau W, Kwait G, Goetzl EJ: Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225:743-745, 1984
5. 4. Proc Natl Acad Sci U S A 81:3501-3505, 1984
6. + lymphocyte phenotype and immunoregulatory functions. J Immunol 135:1357-1360, 1985
7. 4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun 113:531-537, 1983
8. 4, but not by stereoisomers of LTB4 or HETEs. Prostaglandins Leukot Med 13:113-117, 1984
9. Weinblatt M, Kremer J, Helfgott S, Coblyn J, Maier A, Sperling R, Petrillo G, Kesterson J, Dube L, Henson B, Teoh H, Rubin P: A 5-lipoxygenase inhibitor in rheumatoid arthritis (abstract). Arthritis Rheum 33 (suppl 9):S152, 1990
10. Sin YM, Tan CH, Chan SF: Changes in histamine and prostaglandins in acute inflammatory air pouch in mice. Agents Actions 28:98-102, 1989
11. Gado K, Gigler G: Zymosan inflammation: a new method suitable for evaluating new antiinflammatory drugs. Agents Actions 32:119-121, 1991
12. Tarayre JP, Delhon A, Aliaga M, Barbara M, Bruniquel F, Caillol V, Puech L, Consul N, Tisne-Versailles J: Pharmacological studies on zymosan inflammation in rats and mice. I. Zymosan-induced paw oedema in rats and mice. Pharmacol Res 21:375-384, 1989
13. Doherty NS, Poubelle P, Borgeat P, Beaver TM, Westrich GL, Schrader NL: Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. Prostaglandins 30:769-789, 1985
14. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Muller-Peddinghaus R: Mode of action of the ieukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions 43:64-68, 1994
15. Fruchtmann R, Mohrs K-H, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Muller-Peddinghaus R: In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 38:188-195, 1993
16. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Muller-Peddinghaus R: Mode of action of the selective leukotriene synthesis inhibitor Bay X 1005 [(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid] and structurally related compounds. Biochem Pharmacol 45:101-111, 1993
17. Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Muller-Peddinghaus R, Taylor WA: Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol 258:95-102, 1994
18. Gorenne I, Labat C, Gascard JP, Norel X, Muller-Peddinghaus R, Mohrs KH, Taylor WA, Gardiner PJ, Brink C: (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl]acetic acid (BAY X1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 268:868-872, 1994
19. Muller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Buhner K, Ahr H, Mohrs K-H: Bay x1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther 267:51-57, 1993
20. Pearson CM: Development of arthritis, periarthritis and periostitiis in rats given adjuvants. Proc Soc Exp Biol Med 91:95-101, 1956
21. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146: 828-833, 1977
22. Edwards JCW, Sedgewick AD, Willoughby DA: The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol 134:147-156, 1991
23. Sedgwick AD, Koh MS, Willoughby DA, Pelletier M: Effects of sera and exudate from carrageenan-treated rats on two models of acute inflammation. Agents Actions 11:477-481, 1981
24. Sedgwick AD. Lees P: Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents Actions 18:429-438, 1986
25. Phadke K, Fouts R, Parrish J, Butler L: Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharmacology 10:51-60, 1985
26. Griswold DE, Hillegass LM, Meunier PC, DiMartino MJ, Hanna N: Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. Arthritis Rheum 31:1406-1412, 1988
27. Sayers TJ, Wiltrout TA, Bull CA, Denn AC III, Pilano AM, Lokesh B: Effects of cytokines in polymorphonuclear neutrophil infiltration in the mouse. J Immunol 141:1670-1677, 1988
28. 4 in mouse peritonitis. Inflammation 15:251-258, 1991
29. Ford-Hutchinson AW: Leukotrienes: their formation and roles as inflammatory mediators. Fed Proc 44:25-29, 1985
30. Griswold DE, Hoffstein S, Marshall PJ, Webb EF, Hillegass L, Bender PE, Hanna N: Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493. Inflammation 13:727-739, 1989
31. Higgs GA, Follenfant RL, Garland LG: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on acute inflammatory responses. Br J Pharmacol 94: 547-551, 1988
32. 4 antagonist with oral activity in the murine collagen-induced arthritis model. Med Chem 37: 3197-3199, 1994
33. 4 plays a critical role in the progression of collagen induced arthritis. Proc Natl Acad Sci U S A 92:517-521, 1995
34. Henderson B, Hardingham T, Blake S, Lewthwaite J: Experimental arthritis models in the study of the mechanisms of articular cartilage loss in rheumatoid arthritis. Agents Actions Suppl 39:15-26 1993